These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 24585723)

  • 21. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
    Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
    BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
    Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
    Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
    Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
    Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome.
    Saridaki Z; Papadatos-Pastos D; Tzardi M; Mavroudis D; Bairaktari E; Arvanity H; Stathopoulos E; Georgoulias V; Souglakos J
    Br J Cancer; 2010 Jun; 102(12):1762-8. PubMed ID: 20485284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroendocrine Differentiation, Microsatellite Instability, and Tumor-infiltrating Lymphocytes in Advanced Colorectal Cancer With BRAF Mutation.
    Digiacomo N; Bolzacchini E; Veronesi G; Cerutti R; Sahnane N; Pinotti G; Bregni M; Artale S; Verusio C; Crivelli F; Capella C; Sessa F; Furlan D
    Clin Colorectal Cancer; 2019 Jun; 18(2):e251-e260. PubMed ID: 30638691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer.
    Tan E; Whiting J; Xie H; Imanirad I; Carballido E; Felder S; Frakes J; Mo Q; Walko C; Permuth JB; Sommerer K; Kim R; Anaya DA; Fleming JB; Sahin IH
    Oncologist; 2022 Mar; 27(3):191-197. PubMed ID: 35274712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
    J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
    Tie J; Gibbs P; Lipton L; Christie M; Jorissen RN; Burgess AW; Croxford M; Jones I; Langland R; Kosmider S; McKay D; Bollag G; Nolop K; Sieber OM; Desai J
    Int J Cancer; 2011 May; 128(9):2075-84. PubMed ID: 20635392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
    Ogino S; Shima K; Meyerhardt JA; McCleary NJ; Ng K; Hollis D; Saltz LB; Mayer RJ; Schaefer P; Whittom R; Hantel A; Benson AB; Spiegelman D; Goldberg RM; Bertagnolli MM; Fuchs CS
    Clin Cancer Res; 2012 Feb; 18(3):890-900. PubMed ID: 22147942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic pattern is a prognostic factor in BRAF
    Ji J; Sandhu J; Wang C; Fakih M
    Cancer Treat Res Commun; 2023; 35():100714. PubMed ID: 37126990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
    Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Garcia-Carbonero N; Martinez-Useros J; Li W; Orta A; Perez N; Carames C; Hernandez T; Moreno I; Serrano G; Garcia-Foncillas J
    Cells; 2020 Jan; 9(1):. PubMed ID: 31952366
    [No Abstract]   [Full Text] [Related]  

  • 35. Oncologic relevance of genetic alterations in sporadic synchronous and solitary colorectal cancer: a retrospective multicenter study.
    Son IT; Kim M; Oh BY; Kim MJ; Yoon SN; Park JH; Kim BC; Kim JW
    BMC Gastroenterol; 2023 Sep; 23(1):297. PubMed ID: 37667167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics.
    Phipps AI; Buchanan DD; Makar KW; Burnett-Hartman AN; Coghill AE; Passarelli MN; Baron JA; Ahnen DJ; Win AK; Potter JD; Newcomb PA
    Cancer Epidemiol Biomarkers Prev; 2012 Oct; 21(10):1792-8. PubMed ID: 22899730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.
    Lenos K; Goos JA; Vuist IM; den Uil SH; Delis-van Diemen PM; Belt EJ; Stockmann HB; Bril H; de Wit M; Carvalho B; Giblett S; Pritchard CA; Meijer GA; van Kooyk Y; Fijneman RJ; van Vliet SJ
    Oncotarget; 2015 Sep; 6(28):26278-90. PubMed ID: 26172302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials.
    Taieb J; Sinicrope FA; Pederson L; Lonardi S; Alberts SR; George TJ; Yothers G; Van Cutsem E; Saltz L; Ogino S; Kerr R; Yoshino T; Goldberg RM; André T; Laurent-Puig P; Shi Q
    Ann Oncol; 2023 Nov; 34(11):1025-1034. PubMed ID: 37619846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microsatellite Instability with BRAF V600E Associated with Delayed Presentation but Poor Survival in Stage III Colorectal Cancer.
    Karki S; Sun W; Madan R; Lamsal K; Schmitt S; Godwin AK; Kasi A
    Fortune J Health Sci; 2023; 6(2):167-173. PubMed ID: 37736078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer.
    Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
    Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.